Nothing Special   »   [go: up one dir, main page]

WO1998054213A3 - Neurotrophic factor receptors - Google Patents

Neurotrophic factor receptors Download PDF

Info

Publication number
WO1998054213A3
WO1998054213A3 PCT/US1998/008486 US9808486W WO9854213A3 WO 1998054213 A3 WO1998054213 A3 WO 1998054213A3 US 9808486 W US9808486 W US 9808486W WO 9854213 A3 WO9854213 A3 WO 9854213A3
Authority
WO
WIPO (PCT)
Prior art keywords
gdnf
gdnfr
neurotrophic factor
found
present
Prior art date
Application number
PCT/US1998/008486
Other languages
French (fr)
Other versions
WO1998054213A2 (en
WO1998054213B1 (en
Inventor
Gary M Fox
Shuqian Jing
Duanzhi Wen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/866,354 external-priority patent/US7138251B1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CA002291608A priority Critical patent/CA2291608C/en
Priority to AU71659/98A priority patent/AU7165998A/en
Priority to JP50067499A priority patent/JP2002505576A/en
Priority to EP98918805A priority patent/EP0983354A2/en
Publication of WO1998054213A2 publication Critical patent/WO1998054213A2/en
Publication of WO1998054213A3 publication Critical patent/WO1998054213A3/en
Publication of WO1998054213B1 publication Critical patent/WO1998054213B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of receptors for GDNF. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmenbrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.
PCT/US1998/008486 1997-05-30 1998-04-27 Neurotrophic factor receptors WO1998054213A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002291608A CA2291608C (en) 1997-05-30 1998-04-27 Neurotrophic factor receptors
AU71659/98A AU7165998A (en) 1997-05-30 1998-04-27 Neurotrophic factor receptors
JP50067499A JP2002505576A (en) 1997-05-30 1998-04-27 Neurotrophic factor receptor
EP98918805A EP0983354A2 (en) 1997-05-30 1998-04-27 Neurotrophic factor receptors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/866,354 1997-05-30
US08/866,354 US7138251B1 (en) 1996-04-22 1997-05-30 Polynucleotides encoding a neurotrophic factor receptor

Publications (3)

Publication Number Publication Date
WO1998054213A2 WO1998054213A2 (en) 1998-12-03
WO1998054213A3 true WO1998054213A3 (en) 1999-01-07
WO1998054213B1 WO1998054213B1 (en) 1999-02-18

Family

ID=25347430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008486 WO1998054213A2 (en) 1997-05-30 1998-04-27 Neurotrophic factor receptors

Country Status (6)

Country Link
EP (1) EP0983354A2 (en)
JP (1) JP2002505576A (en)
AU (1) AU7165998A (en)
CA (1) CA2291608C (en)
WO (1) WO1998054213A2 (en)
ZA (1) ZA984404B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6677135B1 (en) 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
AU741208B2 (en) * 1997-05-22 2001-11-22 Urmas Arumae Glial cell line-derived neurotrophic factor receptors
AU765070B2 (en) * 1998-03-23 2003-09-11 Genentech Inc. GFRalpha3 and its uses
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (en) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-encoding DNA, parts thereof and GDNF variants
CN110461880A (en) 2016-11-10 2019-11-15 科乐斯疗法公司 GDNF fused polypeptide and its application method
US20220340643A1 (en) * 2019-09-13 2022-10-27 Rutgers, The State University Of New Jersey Aav-compatible laminin-linker polymerization proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444561A2 (en) * 1990-02-26 1991-09-04 Roche Diagnostics GmbH Method for the immunological determination of ligands
WO1995005452A2 (en) * 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1997040152A1 (en) * 1996-04-22 1997-10-30 Amgen Inc. Glial cell line-derived neurotrophic factor receptor
WO1997044356A2 (en) * 1996-05-08 1997-11-27 Biogen, Inc. RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH
EP0846764A2 (en) * 1996-11-27 1998-06-10 Smithkline Beecham Plc Glial cell line-derived neurotrophic factor alpha receptor family
WO1998036072A1 (en) * 1997-02-18 1998-08-20 Genentech, Inc. Neurturin receptor

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0444561A2 (en) * 1990-02-26 1991-09-04 Roche Diagnostics GmbH Method for the immunological determination of ligands
WO1995005452A2 (en) * 1993-08-12 1995-02-23 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
WO1997040152A1 (en) * 1996-04-22 1997-10-30 Amgen Inc. Glial cell line-derived neurotrophic factor receptor
WO1997044356A2 (en) * 1996-05-08 1997-11-27 Biogen, Inc. RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH
EP0846764A2 (en) * 1996-11-27 1998-06-10 Smithkline Beecham Plc Glial cell line-derived neurotrophic factor alpha receptor family
WO1998036072A1 (en) * 1997-02-18 1998-08-20 Genentech, Inc. Neurturin receptor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BALOH, R. H. ET AL: "TRNR2, A NOVEL RECEPTOR THAT MEDIATES NEURTURIN AND GDNF SIGNALING THROUGH RET", NEURON, vol. 18, May 1997 (1997-05-01), pages 793 - 802, XP002065821 *
DATABASE EMBL - EMROD 9 February 1997 (1997-02-09), WATABE, K.: "Mouse mRNA for GDNF receptor alpha, complete cds.", XP002073411 *
DATABASE EMBL - R53U072 2 June 1997 (1997-06-02), BALOH, R.H. ET AL.: "Homo sapiens GDNF family receptor alpha 2 (GFRalpha2) mRNA, complete cds." *
ECONOMIDES, A.N. ET AL.: "Designer cytokines: targeting actions to cells of choice", SCIENCE, vol. 270, 24 November 1995 (1995-11-24), pages 1351 - 3, XP002072653 *
JING S ET AL: "GDNF-INDUCED ACTIVATION OF THE RET PROTEIN TYROSINE KINASE IS MEDIATED BY GDNFR-ALPHA, A NOVEL RECEPTOR FOR GDNF", CELL, vol. 85, 28 June 1996 (1996-06-28), pages 1113 - 1124, XP002036435 *
SANICOLA M ET AL: "GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR-DEPENDENT RET ACTIVATION CAN BE MEDIATED BY TWO DIFFERENT CELL-SURFACE ACCESSORY PROTEINS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, no. 12, 10 June 1997 (1997-06-10), pages 6238 - 6243, XP002065823 *

Also Published As

Publication number Publication date
JP2002505576A (en) 2002-02-19
EP0983354A2 (en) 2000-03-08
ZA984404B (en) 1998-12-01
CA2291608C (en) 2004-04-13
CA2291608A1 (en) 1998-12-03
WO1998054213A2 (en) 1998-12-03
AU7165998A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
NZ332256A (en) Glial cell line-derived neurotrophic factor (GDNF) receptors and nucleic and amino acid sequences encoding them
WO1997033995A3 (en) Extracellular matrix signalling molecules
WO1998054213A3 (en) Neurotrophic factor receptors
WO2003057725A3 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
WO1998027113A3 (en) Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
Fernández et al. Membrane fractionation of a β-lactoglobulin tryptic digest: Effect of the pH
AU1207301A (en) Stabilized proteins
WO2000034475A3 (en) Grnf4, a gdnf-related neurotrophic factor
IL138593A (en) Glial factor receptor ??3 (gfr??3) polypeptide, nucleic acid encoding the same, process for preparation thereof, vectors, host cells, antibodies, chimeric molecules and use of such gfr??3
IL150885A0 (en) Cyr61 compositions and methods
AU3143897A (en) Oligonucleotides which specifically bind retroviral nucleocapsid proteins
AU2003293959A1 (en) Millisecond activation switch for seven-transmembrane proteins
WO1998054213B1 (en) Neurotrophic factor receptors
WO2002066636A3 (en) T cell receptor variants expressed in mesenchymal cells and uses thereof
Woodman ESCRT-III on endosomes: new functions, new activation pathway
WO2002042458A3 (en) G protein coupled receptors
CA2227554A1 (en) Nucleic sequences coding for melatonin receptors, and uses thereof
WO1999021994A3 (en) Human vesicle membrane protein-like proteins
WO2001087980A3 (en) Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
Mizuno et al. Localization of molecules involved in cytokine receptor signaling in the rat trigeminal ganglion
WO1998042746A3 (en) Synthetic saposin c-derived neurotrophic peptides
WO2001072839A3 (en) Human g-protein coupled receptors
WO2001072838A3 (en) Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
WO2002050273A3 (en) A transmembrane protein as a downstream target of neurotrophin and ephrin receptor tyrosine kinases, dna encoding same monoclonal antibodies thereto
WO2001098360A3 (en) Gp354 nucleic acids and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/010806

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1998918805

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2291608

Country of ref document: CA

Ref country code: CA

Ref document number: 2291608

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1999 500674

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998918805

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642